1,8-Di(acetoxycarbonyl)octan | 20726-35-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,8-Di(acetoxycarbonyl)octan
• 英文别名: Diacetyl decanedioate
• CAS: 20726-35-6
• 化学式: C₁₄H₂₂O₆
• 分子量: 286.325
• InChiKey: WCHUTVZHHBVDGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  癸二酸 、 乙酸酐 反应 1.0h， 以87%的产率得到1,8-Di(acetoxycarbonyl)octan
  参考文献：
  名称：

  Preparation and Characterization of Biodegradable Electrospun Polyanhydride Nano/Microfibers

  摘要：

  可生物降解的聚醚共聚物P(CPP–SA)由对羧基苯氧基丙烷(CPP)和癸二酸(SA)组成，重量比为20:80、35:65和50:50，通过无催化剂熔融缩聚工艺聚合而成。通过傅里叶变换红外光谱(FT-IR)、1H核磁共振(1H-NMR)、乌贝洛德粘度计、差示扫描量热法(DSC)和广角X射线粉末衍射(XRD)对共聚物进行了表征。P(CPP–SA)纳米/微纤维首次通过静电纺丝法制造而成。共聚物具有优异的成纤性能，可获得80-3200 nm的直径范围。通过研究纤维形态的变化、重量损失和降解介质的pH值变化，以纳米/微纤维的形式评估了聚醚共聚物的体外降解。实验结果表明，降解率在第一天很快，在接下来的时间里很慢，此外，降解率随着共聚物中CPP含量的增加而降低。因此，静电纺丝聚醚纳米/微纤维作为药物输送载体和组织工程支架具有强大的潜力。

  DOI：

  10.1166/jnn.2010.2535

文献信息

• [EN] CONTROLLED RELEASE FORMULATIONS FOR THE DELIVERY OF HIF-1 INHIBITORS<br/>[FR] FORMULATIONS À LIBÉRATION CONTRÔLÉE POUR L'ADMINISTRATION D'INHIBITEURS DU HIF-1
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2013138343A1

  公开（公告）日：2013-09-19

  Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. In some cases, one or more HIF-1 inhibitors are dispersed or encapsulated in a polymeric matrix. In preferred embodiments, the one or more HIF- 1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof for administration. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.

  本发明提供了用于输送一种或多种HIF-1抑制剂的控释剂型制剂。这些控释制剂型制剂包含一种或多种HIF-1抑制剂与聚合物载体结合或分散。在某些情况下，一种或多种HIF-1抑制剂分散或封装在聚合物基质中。在优选实施例中，一种或多种HIF-1抑制剂与聚合物共价结合，形成聚合物-药物共轭物。聚合物载体可以形成成植入物、微粒子、纳米粒子或其组合物以供给药。控释HIF-1制剂提供长效治疗效果，同时通过在长时间内释放低水平的一种或多种HIF-1抑制剂和/或HIF-1抑制剂共轭物来降低副作用。用于输送一种或多种HIF-1抑制剂的控释剂型制剂可用于治疗或预防与血管化有关的患者疾病或障碍，包括癌症、肥胖症和激素性黄斑病变等眼部疾病。
• CELLULOSE DERIVATIVES FOR INHIBITING CRYSTALLIZATION OF POORLY WATER-SOLUBLE DRUGS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：US20150004237A1

  公开（公告）日：2015-01-01

  Provided are cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers include cellulose esters of formula I: wherein n of the ω-carboxyalkanoyl group, is 3, 4, 6, or 8 to provide a ω-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from: a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ω-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n=1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone.

  提供了对于抑制药物溶液结晶有用的纤维素酯。具体的聚合物包括式I的纤维素酯：其中ω-羧基烷酰基团的n为3、4、6或8，以提供从琥珀酰基、戊二酰基、己二酰基、癸二酰基和壬二酰基羧基烷酰基中选择的ω-羧基烷酰基；R从氢原子和从乙酰基、丙酰基、丁酰基、戊酰基、己酰基、壬酰基、癸酰基、月桂酰基、棕榈酰基和硬脂酰基羧酸基中选择的脂肪酰基中选择；其中脂肪酰基和ω-羧基烷酰基的总取代度至少为2.0；聚合物包括m个重复单元，其中n为1至1,000,000、10至100,000或100至1,000，例如1至6,000。实施例还包括包含纤维素酯和难溶于水的药物的组合物，该组合物在溶液中与药物单独相比表现出更高的溶解度和稳定性。
• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
  申请人：Nangia Avinash

  公开号：US20100316712A1

  公开（公告）日：2010-12-16

  The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.

  该发明涉及改进某些神经障碍/疾病的治疗，例如帕金森病和其他运动障碍。该发明涉及包含该药物组合的药物配方和剂型；制造药物配方和剂型的方法；以及治疗方法，包括向个体注射该药物组合和剂型。在某些实施例中，药物配方和剂型包括卡比多巴和左旋多巴，适合一次日常用量。
• Poly(ester-anhydrides) Derived from Esters of Hydroxy Acid and Cyclic Anhydrides
  作者：Yuvaraj Arun、Radhakanta Ghosh、Abraham J. Domb

  DOI：10.1021/acs.biomac.2c00542

  日期：2022.8.8

  ricinoleic or other hydroxy acids with anhydrides such as succinic, maleic, and phthalic anhydrides. The hydrophobic side chains are designed closer to anhydride bonds to investigate hindrance to hydrolytic cleavage and anhydride interchange. Polyanhydrides were obtained by the activation of ester-diacid using acetic anhydride followed by melt condensation. The reactions were monitored by NMR, Fourier

  交替结构和疏水侧链阻碍了聚（癸二酸-蓖麻油酸）（P（SA-RA））中的水解裂解和酸酐交换，从而在室温下提供稳定的聚酸酐。在本报告中，设计了一系列聚酸酐，以研究酯键、疏水侧链、苯基部分及其与酸酐键的距离对其稳定性和性能的影响。具有交替结构的聚酸酐是通过由蓖麻油酸或其他羟基酸与酸酐如琥珀酸、马来酸和邻苯二甲酸酐制备的酯二酸聚合而构建的。疏水侧链设计得更接近酸酐键，以研究水解裂解和酸酐交换的阻碍。通过使用乙酸酐活化酯-二酸，然后进行熔融缩合，获得聚酸酐。通过 NMR、傅里叶变换红外 (FTIR) 和凝胶渗透色谱 (GPC) 监测反应。与P(SA-RA)相比，合成的聚(酯-酸酐)链长更短，在室温下是稳定的。水解降解研究表明，聚（蓖麻油酸邻苯二甲酸酯）（PRAP）和聚（羟基硬脂酸邻苯二甲酸酯）（PHSAP）中存在的苯基部分减少了酸酐键的水解。聚（羟基辛酸琥珀酸酯）（PHOAS）在所有测试的聚合物中表
• A phosphine sulfide, a manufacturing process therefor and a use thereof
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP0972776A1

  公开（公告）日：2000-01-19

  A basic organic compound which is soluble in an organic solvent, does not have problems in its preparation or handling and exhibits catalytic activity as a basic compound, is a phosphine sulfide represented by the (1): The phosphine sulfide represented by formula (1), is made by reacting one molecule of thiophosphoryl chloride with three molecules of a phosphorane represented by formula (2): A process for effectively manufacturing a poly(alkylene oxide) involves polymerizing an alkylene oxide in the presence of the above organic compound (phosphine sulfide), or in the presence of the phosphine sulfide and an active hydrogen compound selected from water and organic compounds having a partial structure of -OH or -NH-. A process for manufacturing a 1,2-dioxyethane derivative from an epoxy compound, i.e. manufacturing a 1,2-dioxyethane derivative involves reacting an epoxy compound with a carboxylate, carboxylic anhydride, carbonate or phenol compound, respectively, in the presence of the phosphine sulfide.

  一种可溶于有机溶剂、在制备或处理过程中不会出现问题并具有催化活性的碱性有机化合物是硫化膦，其代表式为（1）： 式（1）代表的硫化膦是由一分子硫代磷酰氯与三分子式（2）代表的磷烷反应制得的： 一种有效制造聚环氧亚烷烃的工艺是在上述有机化合物（硫化膦）存在下，或在硫化膦和选 自水和部分结构为-OH 或-NH-的有机化合物的活性氢化合物存在下，聚合环氧亚烷烃。 由环氧化合物制造 1，2-二氧乙烷衍生物的工艺，即制造 1，2-二氧乙烷衍生物的工艺包括在硫化膦存在下，环氧化合物分别与羧酸盐、羧酸酐、碳酸盐或苯酚化合物反应。